Welcome to our dedicated page for Aspen Aerogels SEC filings (Ticker: ASPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspen Aerogels, Inc. filings document the company's aerogel technology business, operating results and material corporate events. Recent Forms 8-K cover quarterly and annual financial results, Regulation FD disclosures, business developments, manufacturing-facility updates, and amendments to the MidCap Loan Facility and related credit-party obligations.
The filing record also includes proxy materials describing governance, board and compensation matters, executive employment arrangements, equity awards and shareholder voting items. Aspen's disclosures connect its capital structure and credit covenants with operations in Energy Industrial and Thermal Barrier products, including PyroThin, Cryogel and Pyrogel applications.
Aspen Aerogels is holding its 2026 virtual annual stockholder meeting on May 13, 2026, asking investors to elect two directors, ratify KPMG as auditor, approve executive pay and its voting frequency, and support a future move to declassify the board. The board recommends voting for all proposals and choosing “One Year” for say-on-pay frequency.
The proxy also highlights 2025 actions to streamline operations, remove approximately $75 million of structural fixed costs, and strengthen the balance sheet. Aspen ended 2025 with about $159 million in cash and cash equivalents and expects nearly $38 million from a General Motors commercial settlement in Q1 2026, plus potential Plant II asset sales to further reduce debt.
The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting 0 shares of Aspen Aerogels Inc. common stock, representing 0% of the class as reported. The filing explains an internal realignment dated January 12, 2026 that led certain Vanguard subsidiaries to report disaggregated holdings separately.
Aspen Aerogels filed an amended annual report mainly to correct a clerical error in KPMG’s audit discussion of inventory, changing the referenced balance to $38.2 million as of December 31, 2025. The underlying 2025 results show a sharp downturn: revenue fell to $271.1 million from $452.7 million in 2024, and the company posted a net loss of $389.6 million versus prior-year net income of $13.4 million.
The loss was driven largely by the decision to halt construction of the Statesboro, Georgia plant, resulting in $286.6 million of impairment charges and additional losses as assets were reclassified as held for sale. Aspen ended 2025 with $156.9 million of cash and cash equivalents, total assets of $406.7 million, and total liabilities of $171.2 million. Management states it expects existing cash, together with operations and potential financings, to support current requirements and capital spending for at least 12 months.
Aspen Aerogels, Inc. is soliciting proxies for its virtual 2026 annual meeting to be held at 9:30 a.m. Eastern Time on May 13, 2026. Stockholders will vote to elect two directors, ratify KPMG LLP as auditor, and cast non-binding advisory votes on executive compensation, vote frequency, and future declassification of the Board.
The CEO letter highlights operating actions taken in 2025: the company ended the year with approximately $159 million in cash, expects nearly $38 million from General Motors in Q1 2026 related to a commercial settlement, and removed approximately $75 million of structural fixed costs on an annualized basis. Management cites recent awards, including a North Sea subsea contract with expected delivery in Q3 2026 and PyroThin thermal barrier awards with production starts expected in 2027 and 2028. The company is pursuing Plant II asset sales in 2026 to further reduce debt.
Aspen Aerogels, Inc. files its annual report describing a fast-growing but volatile business focused on EV battery thermal barriers and energy industrial insulation. Total revenue was $271.1 million in 2025, compared with $452.7 million in 2024 and $238.7 million in 2023, reflecting a sharp pullback after a strong prior year.
Sales of PyroThin thermal barriers into the EV market reached $168.9 million in 2025, following $306.8 million in 2024 and $110.1 million in 2023, primarily to General Motors. GM alone represented 59% of 2025 revenue and 64% of 2024 revenue, underscoring heavy customer concentration risk.
The company reported a 2025 net loss of $389.6 million and an accumulated deficit of $1,049.8 million as of December 31, 2025, even after earning net income of $13.4 million in 2024. Management highlights ongoing capital needs, debt covenants under its MidCap term loan, and reliance on contract manufacturing in China and unionized operations in Mexico.
Aspen operates a proprietary aerogel platform, with 400 issued patents worldwide, serving EV, refinery, petrochemical, LNG and power customers. It had 854 full-time employees as of December 31, 2025 and generated $172.1 million of U.S. revenue and $99.0 million of international revenue that year.
Aspen Aerogels Chief Commercial Officer Corby C. Whitaker reported a routine tax-related share disposition. On the vesting of Restricted Stock Units, 1,924 shares of Common Stock were withheld by the company at $3.22 per share to cover minimum statutory tax obligations.
After this withholding, Whitaker directly holds 205,315 shares of Common Stock, which the footnotes clarify represent 128,170 shares plus 77,145 RSUs. This event reflects compensation and tax mechanics rather than an open-market trade.
Aspen Aerogels CFO & Treasurer Grant Douglas Thoele reported a routine tax-withholding transaction. On this Form 4, 590 shares of common stock were withheld at $3.22 per share to cover minimum statutory taxes on the vesting of restricted stock units.
After this non-market disposition, Thoele is shown as holding 77,732 common-equivalent units, consisting of 10,111 shares of common stock and 67,621 RSUs. The event reflects compensation-related vesting mechanics rather than an open-market sale.
Aspen Aerogels President and CEO Donald R. Young reported a routine tax-related share disposition. On the vesting of Restricted Stock Units (RSUs), 4,275 shares of Common Stock were withheld by the company to cover minimum statutory tax obligations, at $3.22 per share.
After this withholding, Young holds 637,834 equity-based units, consisting of 438,349 shares of Common Stock and 199,485 RSUs. This event reflects compensation-related tax settlement rather than an open-market sale.
ASPEN AEROGELS INC Chief Operating Officer Gregg Landes reported a routine tax-related share disposition. The company withheld 1,924 shares of common stock at $3.22 per share to cover minimum statutory taxes on vesting of restricted stock units. After this withholding, Landes holds 102,931 equity-linked units, including 26,317 shares of common stock and 76,614 restricted stock units.
Aspen Aerogels President and CEO Donald R. Young reported equity compensation grants and related tax withholding transactions. On March 4, he acquired 156,716 shares of Common Stock and 212,249 stock options at a grant price of $0.00 per share through awards.
The restricted stock units vest in three equal installments on March 4, 2027, March 4, 2028, and March 4, 2029, and the options follow the same one-third annual vesting schedule. On March 5, 8,618 shares of Common Stock at $3.27 per share were withheld by the company to cover minimum statutory taxes on RSU vesting, leaving him with 642,109 directly held shares, including 430,387 shares of Common Stock and 211,722 RSUs.